JAZZ - Jazz Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

155.64

-2.31 (-1.46%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	157.95
Open	158.31
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	154.91 - 158.68
52 Week Range	128.58 - 163.75
Volume	220,142
Avg. Volume	415,591

Market Cap	9.308B
Beta	1.31
PE Ratio (TTM)	19.55
EPS (TTM)	7.96
Earnings Date	May 7, 2018 - May 11, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	182.54

Trade prices are not sourced from all markets

All

News

Press Releases

Yahoo Finance Contributorsyesterday
5 Trade Ideas for Monday: Globus Medical, Interactive Brokers, Infinera, Jazz Pharmaceuticals & Kansas City Southern
Market Realist5 days ago
Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.
Market Realist5 days ago
Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
Market Realist5 days ago
Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.
Market Realist5 days ago
Jazz Pharmaceuticals: How It’s Positioned before 1Q18
In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.
GlobeNewswire15 days ago
Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit25 days ago
See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
Benzingalast month
Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential
Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) in a Monday report. The Analyst Analyst David Risinger upgraded shares of Jazz ...
Zackslast month
Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock?
Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.
Markitlast month
See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
GlobeNewswirelast month
New Research: Key Drivers of Growth for Jazz Pharmaceuticals, Armstrong World Industries, Banco Latinoamericano de Comercio Exterior, S.A, Mercury, Canadian National Railway, and Bank of Nova Scotia — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Investopedia2 months ago
Why Biotech Stocks Face Steep Declines Ahead
The biotech sector could sink in the near term amid signs of deteriorating technicals.
PR Newswire2 months ago
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
Cowen and Company 38th Annual Healthcare Conference in Boston, MA on Tuesday, March 13, 2018 at 8:00 a.m. EDT / 12:00 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update. Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 14, 2018 at 8:00 a.m. EDT / 12:00 p.m. GMT. Matt Young, executive vice president and chief financial officer, will provide an overview of the company and a business and financial update. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
PR Newswire2 months ago
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
DUBLIN, March 2, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard review the company's New Drug Application (NDA) seeking marketing approval for solriamfetol, an investigational medicine for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is December 20, 2018.
Thomson Reuters StreetEvents2 months ago
Edited Transcript of JAZZ earnings conference call or presentation 27-Feb-18 9:30pm GMT
Q4 2017 Jazz Pharmaceuticals PLC Earnings Call
Zacks2 months ago
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
Associated Press2 months ago
Jazz misses Street 4Q forecasts
The Dublin-based company said it had profit of $3.79 per share. Earnings, adjusted for one-time gains and costs, were $2.95 per share. The results fell short of Wall Street expectations. The average estimate ...
Investor's Business Daily2 months ago
Jazz Pharma's Fourth-Quarter Sales, Profit Lag; Guidance Mixed
Jazz reported adjusted income of $2.95 per share on sales of $436.4 million for its fourth quarter.
PR Newswire2 months ago
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results
Total Revenues of $1.6 Billion in 2017 GAAP EPS of $7.96 Per Share in 2017 Adjusted Non-GAAP EPS of $11.04 Per Share in 2017 Solriamfetol New Drug Application Submitted in December 2017 DUBLIN , Feb. 27, ...
ACCESSWIRE2 months ago
Jazz Pharmaceuticals Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Jazz Pharmaceuticals Plc (NASDAQ: JAZZ ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern ...
Benzinga2 months ago
Jazz Pharmaceuticals Q4 Earnings Outlook
On Tuesday, Jazz Pharmaceuticals (NASDAQ: JAZZ ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Wall Street expects EPS of $3.00 and sales around ...
ACCESSWIRE2 months ago
Wired News - Jazz Pharma Enrolled First Patient in Phase-2 Clinical Trial Assessing Defibrotide for the Prevention of Acute Graft-versus-Host Disease
Stock Monitor: Anika Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Jazz Pharma PLC (NASDAQ: JAZZ ). ...
Benzinga2 months ago
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
PR Newswire2 months ago
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
DUBLIN , Feb. 23, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the efficacy and safety ...
Zacks2 months ago
Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?
In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.